Lexaria Bioscience Corp. reported earnings results for the third quarter and nine months ended May 31, 2024. For the third quarter, the company reported sales was USD 0.084 million compared to USD 0.077707 million a year ago. Net loss was USD 1.78 million compared to USD 2.37 million a year ago. Basic loss per share from continuing operations was USD 0.13 compared to USD 0.37 a year ago.
For the nine months, sales was USD 0.380278 million compared to USD 0.195467 million a year ago. Net loss was USD 3.61 million compared to USD 5.43 million a year ago. Basic loss per share from continuing operations was USD 0.32 compared to USD 0.89 a year ago.